Related Experiment Video
Updated: May 5, 2026
10:24
Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
Published on: February 12, 2018
9.7K
[Randomized clinical trials in diabetic macular edema]
Archivos De La Sociedad Espanola De Oftalmologia
|November 27, 2013
Summary
Diabetic macular edema (DME) treatment has advanced with anti-vascular endothelial growth factor (VEGF) drugs. Ranibizumab shows encouraging results in improving vision for DME patients, offering a new therapeutic option.
Area of Science:
- Ophthalmology
- Endocrinology
- Pharmacology
Context:
- Diabetic macular edema (DME) is a leading cause of vision loss in diabetic individuals.
- Current treatments like laser photocoagulation often fail to restore or preserve vision.
- Vascular endothelial growth factor (VEGF) is implicated in DME pathogenesis.
Purpose:
- To review the clinical evidence supporting ranibizumab for DME treatment.
- To evaluate the efficacy and safety of ranibizumab based on randomized clinical trials.
Summary:
- Ranibizumab, an anti-VEGF intravitreal drug, represents a significant advancement in DME management.
- Randomized clinical trials demonstrate ranibizumab's therapeutic effects and safety profile.
- Evidence suggests ranibizumab can improve visual acuity in patients with DME.
Impact:
- Introduces a novel therapeutic strategy for a common complication of diabetes.
- Offers potential for vision improvement in patients previously unresponsive to laser therapy.
- Highlights the role of anti-VEGF therapy in managing diabetic retinopathy complications.
Related Concept Videos
01:27Diabetic Retinopathy
65
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
65
01:27Open Angle Glaucoma: Treatment
1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
01:28Diabetic Nephropathy
49
Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration...
49
01:28Angle Closure Glaucoma: Treatment
1.7K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.7K